Background {#Sec1}
==========

Critically ill patients with sepsis are frequently anemic. The underlying pathophysiology is multifactorial and includes production of inflammatory cytokines that increase hepcidin which reduces iron availability \[[@CR1]\], dilution due to fluid therapy, and blood loss \[[@CR2]\]. Red blood cell (RBC) transfusions to correct anemia can be life-saving but are also associated with a number of potential adverse effects which makes risk--benefit assessment challenging \[[@CR3]--[@CR5]\]. The adverse effects include infections, hemolytic reactions, transfusion-related acute lung injury (TRALI), pulmonary edema due to volume overload (transfusion-associated cardiac overload, TACO) and effects on the immune system with transfusion-related immunomodulation (TRIM) \[[@CR6]\].

The clinical impact of the adverse effects on morbidity and mortality of transfusion of RBCs in sepsis has been investigated in randomized controlled trials (RCT) \[[@CR7]--[@CR9]\]. In the subgroup analyses of septic patients in the TRICC trail \[[@CR7]\] and in the TRISS trail \[[@CR8]\], a liberal RBC transfusion strategy (hemoglobin level \> 90--100 g/L) did not confer a benefit as compared to a restrictive strategy (hemoglobin level \> 70 g/L). However, in the TRICOP trial, performed in a cohort of septic oncology patients, a liberal transfusion strategy was associated with a lower 90-day mortality \[[@CR9]\]. Furthermore, observational studies have also demonstrated positive effects of RBC transfusions. \[[@CR10], [@CR11]\].

Thus, these data are inconclusive and areas of uncertainty remain. In the RCTs, the time between admission and inclusion was 6 h or longer, which means that the effect of any RBC transfusion given early in the course of sepsis was not studied. Moreover, patients in the restrictive group received on average one unit of blood, meaning that the potential adverse effects of a low dose of RBC transfusion could not be assessed. Furthermore, a higher proportion of patients in the restrictive group discontinued the study which could have biased the results.

In an attempt to address some of these uncertainties, we propensity score-matched patients with severe sepsis or septic shock who received low-grade RBC transfusions any of the first 5 days after intensive care unit (ICU) admission to those who did not receive RBC transfusions and evaluated the effect on mortality and organ failure.

Methods {#Sec2}
=======

Data collection and study population {#Sec3}
------------------------------------

This study was approved by Swedish Ethical Review Authority in Lund, Sweden (registration numbers 2014/916 and 2018/866). All participants were offered an opt-out via advertisement in the local newspaper and the board waived the requirement for written informed consent. The manuscript was prepared according to the STROBE guidelines for observational studies \[[@CR12]\].

All patients ≥ the age of 18 admitted to the 9-bed general ICU at Skåne University Hospital, Lund, Sweden between 2007 and 2018 with severe sepsis or septic shock according to the Sepsis-2 definition were eligible for inclusion \[[@CR13]\]. For patients with multiple admissions with the diagnosis of severe sepsis or septic shock, only the first admission was included in the study. Day 0 started at admission and ended at 06:00. As described above, a condition with massive bleeding can affect outcome and patients who received high-grade RBC transfusion (\> 670 ml \[= more than 2 units\]) during the first 5 days were, therefore, excluded. RBC transfusions were given at the discretion of the treating physician but in local guidelines, it was recommended to keep hemoglobin level above 100 g/L in critically ill patients with severe sepsis or septic shock.

Mortality data were extracted from the Swedish intensive care quality register PASIVA (Otimo Data AB, Kalmar, Sweden). Physiological and laboratory data and pre-existing conditions (age, gender, chronic obstructive pulmonary disease (COPD), renal failure, diabetes), outcome variables (except mortality) and fluid administration data were collected from raw data, i.e., from the electronic master chart system of the hospital (Melior, Cerner, N. Kansas City, MO, USA), or from the patient data management system at the ICU (Intellispace critical care and anaesthesia (ICCA), Philips, Amsterdam, the Netherlands).

Outcome variables {#Sec4}
-----------------

Mortality was assessed at 90 and 180 days after ICU admission. Organ support was assessed by calculating days alive and free (DAF) of organ support for the first 28 days after admission to the ICU \[[@CR14]\]. For patients who died in the ICU, we counted the days without the specified organ support before death. Organ support measures were vasopressors for circulatory failure, mechanical invasive ventilation for respiratory failure and renal replacement therapy (RRT) for kidney failure. To further assess organ failure, the maximum sequential organ failure assessment (SOFA) score during the first 28 days after admission was analyzed. Kidney failure was also evaluated according to the acute kidney injury network (AKIN) scoring system \[[@CR15]\]. The maximal AKIN score the first 10 days after ICU admission was used for analysis.

Statistics {#Sec5}
----------

Patients receiving low-grade RBC transfusion during the first 5 days of ICU admission were propensity score matched with non-transfused patients to adjust for differences in baseline variables associated with outcome. The propensity score was calculated with linear logistic regression using a one-to-many macro for SAS \[Parsons 2004\] with the covariates specified in Table [1](#Tab1){ref-type="table"}. Physiological and laboratory variables used in the propensity score matching were collected within 90 min of admission to the ICU. Note that the hemoglobin value at admission was not included in the matching in the primary analysis. In a secondary sensitivity analysis, the median hemoglobin value day 0 was included in the matching. A greedy matching procedure in both the primary and secondary analyses matched treated to controls at a ratio of 1:1. In a first step, a match was sought with a propensity score that was identical to 8 decimal places to the treated patient. If no match was found, a match would be sought at 7 decimal places and so on. If no match was found at one decimal place, the patient receiving RBC transfusion was excluded from the study. A control could only be used once. A standardized difference of \< 10% has previously been suggested to indicate negligible differences in the mean or prevalence of covariates between groups \[[@CR16], [@CR17]\].Table 1Patient demographics before and after propensity matchingUnmatched groupsStandardized difference*P* valuePropensity-matched groupsStandardized difference*P* valueControl *N* = 405RBC^a^*N* = 459Control *N* = 237RBC *N* = 237Pre-existing conditions Age, mean (SD^b^)64 (16)65 (15)0.0470.49065 (15)65 (15)0.0100.914 Male gender, no (%)233 (57)234 (51)0.1310.054130 (55)138 (58)0.0680.460 Blood malignancy^c^, no (%)16 (4.4)42 (9.2)0.1870.00712 (5.1)14 (5.9)0.0370.687 COPD^d^, no (%)42 (10) (0.305)52 (11)0.0300.65229 (12)28 (12)0.0130.888 Cirrhosis, no (%)17 (4.2)12 (2.6)0.0870.19811 (4.6)8 (3.4)0.0650.483 Immunosuppression^e^, no (%)30 (7.4)54 (12)0.1480.03118 (7.6)19 (8.0)0.0160.864 Malignancy^f^, no (%)43 (11)73 (16)0.1560.02331 (13)33 (14)0.0250.789 Nosocomial infection^g^, no (%)33 (8.1)44 (9.6)0.0510.46021 (8.9)24 (10)0.0430.639 Airway infection, no (%)112 (28)116 (25)0.0540.42863 (27)63 (2701.000 Surgery^h^, no (%)64 (16)99 (22)0.1480.03140 (17)48 (20)0.0870.346 GI^i^-bleeding, no (%)0 (0)6 (1.3)0.1630.0210 (0)0 (0)0.0001.000 DIC^j^, no (%)25 (6.2)33 (7.2)0.0410.55219 (8.0)14 (5.9)0.0830.368 I.C.^k^ volume effect, no (%)2 (0.5)4 (0.9)0.0460.5052 (0.8)2 (0.8)01.000Physiological and laboratory variables at admission^l^, mean (SD) Heart rate, mean (SD)107 (23)109 (24)0.0850.216106 (23)106 (25)0.0130.889 SBP^m^, (mmHg)108 (30)107 (29)0.0520.450107 (30)108 (31)0.0440.634 Lactate (mmol/L)3.4 (3.2)3.5 (2.7)0.0270.6913.4 (3.2)3.4 (2.7)00.996 Norepinephrine (µg/min)7.0 (12)11.6 (20)0.285\< 0.0019.0 (13)7.7 (11)0.1080.241 Temperature (°Celcius)37.4 (1.5)37.4 (1.4)0.0350.61737.3 (1.5)37.3 (1.4)0.0070.940 PaO~2~/FiO~2~ (kPa)23 (15)22 (16)0.0400.58823 (15)22 (15)0.0400.665 Leucocytes (× 10^9^/L)16 (18)14 (19)0.0930.19716 (20)15 (20)0.0380.683 Platelets (× 10^9^/L)188 (130)182 (135)0.0440.517187 (129)185 (120)0.0180.845 pH7.13 (1.5)7.31 (0.50)0.261\<0.0017.34 (0.12)7.34 (0.11)0.0420.647 Bilirubin (µmol/L)24 (35)25 (46)0.0100.89124 (33)26 (50)0.0530.561 Creatinine (µmol/L)172 (126)180 (141)0.0630.360181(130)175 (133)0.0420.645 PT/INR^n^1.58 (0.85)1.62 (0.82)0.0400.5501.58 (0.70)1.59 (0.78)0.0050.956 APTT^o^ (sec)42 (19)45 (17)0.1780.00943 (18)42 (14)0.0500.586^a^Low-grade red blood cell transfusion defined as \< 670 ml any of the first 5 days^b^Standard deviation^c^Lymphoma, acute leukaemia or myeloma^d^Chronic obstructive pulmonary disease^e^Chronic steroid treatment correlative to ≥ 0.3 mg/kg prednisolone/day, radiation, or chemo therapy^f^Cancer spread beyond the regional lymph nodes^g^Infection that developed after ≥ 48 h in hospital or secondary to surgical or medical procedure^h^Before admission to intensive care^i^Gastro-intestinal^j^Disseminated intravascular coagulopathy^k^Intra-cranial^l^First value within 90 min after admission except for "Norepinephrine" which is the mean dose the first 12 h^m^Systolic blood pressure^n^Prothrombin time^o^Activated partial thromboplastin time

Sample size was based on the number of available patients during the study period. Variables were summarized using mean or median with standard deviation or range as distribution measurement. The propensity score matching was performed using SAS version 9.4 (SAS Institute Inc., Cary, NC, USA) prior to any comparison between the groups. Kaplan--Meier survival analysis was performed and is presented in graphs with corresponding stratified log-rank test. In accordance with the previous recommendations \[[@CR18]\] comparisons between the groups after propensity score matching was performed with paired hypothesis testing using SPSS Statistics version 24 (SPSS Inc., Chicago, Ill., USA). A two-sided P value of less than 0.05 was considered to indicate statistical significance. Continuous variables are presented as median (interquartile range) and all categorical variables are presented as numbers (percentage).

Results {#Sec6}
=======

Study population and propensity score match {#Sec7}
-------------------------------------------

Of 9490 ICU admissions 1347 were diagnosed with severe sepsis or septic shock. After elimination of multiple admissions, age \< 18 and patients who received high-grade transfusion, 864 patients were included. The propensity score match of these patients resulted in 237 patients in the RBC group and 237 patients in the control group (Fig. [1](#Fig1){ref-type="fig"}). The rate of inclusion per year in respective group is illustrated in Additional file [1](#MOESM1){ref-type="media"}. Baseline values including comorbidity, special treatments, vital signs and laboratory results at admission in the unmatched and matched study population are summarized in Tables [1](#Tab1){ref-type="table"} and [2](#Tab2){ref-type="table"}. Matching reduced standardized difference between the groups in baseline characteristics to less than 10% for all variables except norepinephrine. For baseline variables not included in the matching, differences between the groups were eliminated after the matching for all variables except for "Reason for admission, Gastric", Table [2](#Tab2){ref-type="table"}.Fig. 1Consort diagramTable 2Unmatched baseline characteristicsUnmatched groupsPropensity-matched groupsControls, *n* = 405RBC^a^, *n* = 459*P*-value^b^Controls, *n* = 237RBC, *n* = 237*P* value^c^SAPS 3^d^, median (IQR^e^)66 (58--77)71 (62--81)\< 0.00169 (60--80)69 (59--79)N.S.First SOFA^f^8 (5--10)9 (6--11)\< 0.0018 (5--11)8 (5--10)N.S.Days before ICU^g^0 (0--2)1 (0--5)\< 0.0010 (0--2)1 (0--3)N.S.Reasons for admission^h^, *n* (%) CNS^i^91 (22)92 (20)N.S.58 (25)57 (24)N.S. Hematologic39 (9.6)64 (14)N.S.26 (11)27 (11)N.S. Gastric88 (22)148 (32)\< 0.00151 (21)74 (31)0.02 Metabolic82 (20)95 (21)N.S.53 (22)51 (21)N.S. Respiratory188 (146)239 (52)N.S111 (47)130 (55)N.S. Cardiovascular67 (17)75 (16)N.S.35 (15)41 (17)N.S. Hepatic29 (7.2)43 (9.4)N.S.22 (9.3)22 (9.3)N.S. Renal138 (34)160 (35)N.S.89 (38)93 (39)N.S. Other42 (10)34 (7.4)N.S.24 (10)26 (11)N.S.Arrival route *n* (%) Emergency department115 (28)93 (20)0.00764 (27)54 (23)N.S. General ward199 (49)232 (51)N.S.128 (54)120 (51)N.S. Intermediate care7 (1.7)19 (4.1)0.0463 (1.3)11 (4.6)N.S. Operation30 (7.4)37 (8.0)N.S.21 (8.9)22 (9.2)N.S. Other ICU39 (9.6)48 (10)N.S.20 (8.4)29 (12)N.S. Other arrival route15 (3.7)30 (6.5)N.S.1 (0.42)1 (0.42)N.S.^a^Red blood cell transfusion^b^Mann--Whitney or Chi-2 test^c^Wilcoxon rank sum or McNemar´s test^d^Simplified acute physiology score 3^e^Interquartile range^f^Sequential organ failure assessment^g^Days on hospital before admission to the intensive care unit^h^Patients may have more than one reason for admission^i^Central nervous system

All RBC transfusions were leucoreduced. Median hemoglobin level in the RBC group immediately before RBC transfusion was 95 g/L (88--104). Immediately after the RBC transfusion, the median hemoglobin level was 101 g/L (93--109). The median hemoglobin level on day 0 was 103 g/L (95--108) for the RBC group and 117 g/L (104--131) for the control group (*P* \< 0.001). Daily hemoglobin levels during the first 5 days of ICU admission in both groups are shown in Fig. [2](#Fig2){ref-type="fig"}. The median volume of RBC transfusion in the RBC group the first five days after admission was 177 ml/day (110--291). The majority of patients were transfused during the first 2 days of admission (Fig. [3](#Fig3){ref-type="fig"}).Fig. 2Median hemoglobin level with interquartile range. RBC = group with patients who received red blood cell transfusion any of the first 5 daysFig. 3Mean red blood cell transfusion per day with 95% confidence interval in the RBC group. RBC = group

Outcomes {#Sec8}
--------

Detailed results of the outcome measures are presented in Table [3](#Tab3){ref-type="table"}. In summary, mortality for patients in the RBC group was higher at 90 and 180 days compared to patients in the control group (Table [3](#Tab3){ref-type="table"} and Fig. [4](#Fig4){ref-type="fig"}). The absolute risk increase for death at 180 days for patients in the RBC group was 11% (95% CI 1.7--19%); (*P* = 0.018). The AKIN max was higher in the RBC group and patients in the RBC group were more likely to receive RRT, compared to patients in the control group. There was no difference in DAF of RRT between the groups. DAF of vasopressors and mechanical ventilation was lower in the RBC group than in the control group, indicating more pronounced circulatory and respiratory failure in the RBC group. Patients in the RBC group demonstrated a higher median SOFA-max score than patients in the control group.Table 3Main outcome variablesOutcomePropensity-matched groupsRelative risk (95% CI^a^)Absolute risk increase (95% CI)*P*^b^Control *n* = 237RBC^c^*n* = 23790-day mortality80 (34)102 (43)1.28 (1.01--1.61)9.3% (0.6--18%)0.032180-day mortality91 (38)116 (49)1.27 (1.04--1.57)11% (1.7--19%)0.018RRT^d^21 (8.9)48 (20)2.29 (1.41--3.69)11% (5.1--18%)0.001AKIN0 (0--2)0 (0--3)0.001DAF^e^ of RRT28 (16--28)28 (9--28)0.29DAF of vasopressors26 (13--27)23 (7--26)0.009DAF of mechanical ventilation26 (12--28)21 (4--27)0.002SOFA max^f^9 (7--12)11 (8--13)\< 0.001Data are presented as number (%) or median (interquartile range)^a^Confidence interval^b^Wilcoxon rank sum or McNemar´s test^c^Low-grade red blood cell transfusion defined as \< 670 ml any of the first 5 days^d^Renal Replacement Therapy^e^Days Alive and Free^f^Sequential Organ Failure Assessment score the first 10 days after admissionFig. 4Kaplan--Meier curves of 180-day survival in the control group (blue line) and the RBC group (red line) (*P* = 0.046, stratified log-rank test). RBC = group with patients who received red blood cell transfusion any of the first 5 days

Fluids and RBC transfusion {#Sec9}
--------------------------

During the first 5 days of ICU stay, there was no difference in crystalloid or colloid administration or total fluid balance between the two groups (Table [4](#Tab4){ref-type="table"}). Patients in the RBC group received more total fluids and produced more urine the first 5 days compared to the control group.Table 4Fluid therapy, first 5 daysFluids per dayPropensity score-matched groups*P*^b^Control, *n* = 237RBC^a^, *n* = 237MedianIQR^c^MediannIQRColloids^d^ (ml)342100--688357206--6210.939Crystalloids^e^ (ml)1200482--25471120500--20150.082Fluids in, total^f^ (ml)34952301--455739203127--4963\< 0.001Urine output (ml)1916429--27722295906--31340.005Total fluid balance^g^ (ml)5440--2066645− 100 to 15680.765RBC transfusion (ml)00--0177110--291\< 0.001For patients with ICU stay \< 5 days, the mean per day was calculated for the length of stay^a^Low-grade red blood cell transfusion defined as \< 670 ml (\< 2 units) any of the first 5 days^b^Wilcoxon rank sum test^c^Interquartile range^d^Defined as albumin (200 mg/ml), albumin (5 mg/ml), dextran 70 (60 mg/ml) and hydroxyethyl starch (200/0.5 and 130/0.4)^e^Crystalloids represents the sum of NaCl 9 mg/ml and Ringer´s Acetate^f^Fluids in, total represents the sum of all enteral and parenteral administered fluids but not RBC transfusions^g^Insensible perspiration and RBC transfusions not included

Sensitivity analysis {#Sec10}
--------------------

The sensitivity analysis was performed to investigate any effects of hemoglobin level at admission on the outcomes. This was done by including the median hemoglobin level the admission day in the matching protocol. In this analysis, the starting point was the same original population of 864 patients with severe sepsis or septic shock as in the main analysis (Fig. [1](#Fig1){ref-type="fig"}). The propensity score matching resulted in 116 patients in the control group and 116 patients in the RBC group. The matching was good with \< 10% standardized difference in all variables except 3 (systolic blood pressure, platelets and creatinine) (Additional file [2](#MOESM2){ref-type="media"}). Median hemoglobin level in the RBC group immediately before RBC transfusion was 95 g/L (88--103). The median hemoglobin level day 0 was 107 g/L (105--110) for the RBC group and 106 g/L (102--111) for the control group. For hemoglobin levels the first 5 days in both groups please see Fig. [5](#Fig5){ref-type="fig"}. The differences between groups were essentially unchanged compared to the primary analyses (Additional file [3](#MOESM3){ref-type="media"}).Fig. 5Median hemoglobin level with interquartile range in the sensitivity analysis that included hemoglobin level day 0 in the matching. RBC = group with patients who received red blood cell transfusion any of the first 5 days

Discussion {#Sec11}
==========

In the present study, low-grade leukoreduced RBC transfusion in critically ill septic patients was associated with increased mortality, increased kidney, circulatory and respiratory failure as well as higher SOFA-max score.

With the propensity score matching, we aimed to create the RBC and the control groups as similar as possible with respect to severity of illness at ICU admission. Because a low hemoglobin at admission may be a result of an underlying condition which may influence outcome independent of RBC transfusions, we performed a sensitivity analysis in which hemoglobin concentration at admission was included in the propensity score matching. Although the results of this analysis are slightly less robust due to the lower number of matched patients and hence lower power, the results were very similar. Further, pre-matching differences between the groups in baseline variables not included in the propensity score matching were erased after the matching for all variables except for "Gastric reason for admission" (Table [2](#Tab2){ref-type="table"}). Taken together, this supports the robustness in the propensity score matching and in the findings in the main analysis.

The observed hemoglobin level of 95 g/L before transfusion may appear high given that current guidelines suggest a transfusion trigger of 70 g/L in the absence of ongoing ischemia. As mentioned above, the present study was performed in an institution with a liberal tradition of RBC transfusions and before the publication of the TRISS trial a transfusion trigger of 100 g/L was accepted in hemodynamically unstable patients with sepsis. After 2014, a more restrictive approach was implemented and the observed hemoglobin level before transfusion, therefore, reflects this change of practice.

In contrast to our results, two randomized trials comparing liberal (hemoglobin level goal \> 90--100 g/L) vs restrictive (\> 70 g/L) transfusion strategy in critically ill patients with sepsis or septic shock did not detect a difference in mortality or need for vasopressors, mechanical ventilation or RRT between the treatment strategies \[[@CR7], [@CR8]\]. It should be noted that previous RCTs on different hemoglobin thresholds for RBC transfusions did not study the possible negative effects of RBC transfusions but rather the effects of different thresholds for RBC transfusions \[[@CR7]--[@CR9]\]. This means that also patients in the low threshold group received a significant number of RBC units. In contrary, the present study included a control group with patients who did not receive any RBC transfusions at all during the study period. Thus, when evaluating if RBC transfusions are harmful, independent of hemoglobin levels within a safe interval, observational studies like the present may have some benefits. Our result demonstrated that the majority of RBCs were administered within the first days after ICU admission. Interestingly, the largest RCT on transfusion thresholds in septic shock to date, the TRISS trial, included patients on average 22 h after admission and could not demonstrate a difference between a low and high transfusion trigger \[[@CR8]\]. This raises the possibility that the effect of transfusions on outcome could be time dependent, in the sense that the early RBC transfusions given to septic patients might be the transfusions with highest risk.

As mentioned above, previous observational studies on the effect of RBC transfusions in sepsis have reported a decrease in mortality \[[@CR10], [@CR11]\]. In contrast to our study, these studies did not exclude patients receiving massive transfusions. Because massive transfusions indicate active bleeding, a condition in which the risk--benefit ratio may favor transfusion, it is possible that this difference in study design may explain the difference in results. Moreover, the average transfused patients in both of these studies were transfused at hemoglobin of 75--80 g/L which could contribute to the difference in results.

What is the potential pathophysiological mechanism of the observed increased mortality and morbidity after RBC low-grade transfusions in our study? As mentioned above, known adverse effects of RBC transfusion include TACO, TRALI and TRIM, all of which may cause negative effects in many organs \[[@CR6]\]. Although patients in the RBC group received more fluids the first 5 days, the fluid balance was not different between the groups, which would indicate that fluid overload (TACO) was not the reason for the differences in outcome. The incidence of TRALI is previously estimated to be about one case per 12 000 transfusions \[[@CR19]\]. Given that TRALI most commonly occurs after plasma transfusion and that no episodes of TRALI presentation were reported for included patients we believe that it is unlikely to the main cause of the differences between the groups even if underreported. TRIM represents an interaction of a multitude of immunomodulatory mediators in the RBC transfusion with the immune system, leading to both proinflammatory and immunosuppressive effects \[[@CR20]\]. In the setting of sepsis, such effects may be deleterious and represents a potential mechanism by which RBCs may adversely affect outcome.

Limitations {#Sec12}
===========

We recognize the limitations in the present study due to its retrospective nature. Although baseline values were carefully adjusted for severity of illness, the presence of undetected factors of relevance for outcome such as differences in comorbidities cannot be ruled out. Further, the study was done at a single department which limits the external validity. The risk--benefit ratio for transfusions is likely to be dependent on the Hb level at which RBC are transfused. Thus, it is important to emphasize that the results may only be valid for the transfusion level observed in our cohort and may not be generalized to other transfusion triggers.

Although there is evidence for the safety of a restrictive transfusion strategy in sepsis, we still lack knowledge of safety in certain sub-populations such as septic patients with myocardial ischemia, severe hypoxemia or acute hemorrhage. Furthermore, the potentially harmful effects of RBC transfusion on morbidity and long-term mortality warrants further evaluation including, e.g., individualized therapy and methods of preventing or treating anemia without RBC transfusion.

Conclusion {#Sec13}
==========

In conclusion, this propensity score-matched study of patients with severe sepsis and septic shock with low-grade or no RBC transfusion indicates increased morbidity and long-term mortality of RBC transfusion in a liberal transfusion setting. These findings support the current Surviving sepsis campaign guidelines of restrictive transfusion strategy \[[@CR21]\].
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